Stopping tirzepatide for a month: what the rebound data actually shows

What's this video probably claiming?

Based on the caption, @pocamillian is documenting a fairly common GLP-1 user experience: she paused tirzepatide injections for about a month, gained roughly 11 pounds back from her lowest recorded weight of 147 pounds, and is now restarting. The implicit claim embedded in "I still feel like I'm doing pretty good" is that short medication breaks are manageable, and that regain during a pause is modest and reversible. She's also signaling that behavioral choices, not just the drug, contributed to the gain. That's actually a more nuanced framing than most GLP-1 content on TikTok, which tends to treat these medications as a one-way switch. The video likely normalizes treatment interruptions and frames restarting as straightforward. Whether that framing holds up against the clinical literature on GLP-1 discontinuation is worth examining carefully.

What does the science actually show?

The discontinuation data on tirzepatide specifically comes largely from the SURMOUNT-4 trial (Aronne et al., 2024, JAMA), which followed participants who had already lost weight on tirzepatide for 36 weeks and then randomized them to continue or switch to placebo. The placebo group regained about two-thirds of their lost weight within 88 weeks of stopping. That's the long-game picture. For shorter interruptions, there's less controlled data, but pharmacokinetically, tirzepatide has a half-life of roughly five days, meaning it clears meaningfully within two to three weeks. Appetite suppression and gastric emptying effects diminish accordingly. A 2022 analysis from the STEP 4 semaglutide trial (Rubino et al., NEJM) showed similar rapid weight rebound after stopping that GLP-1, with participants regaining about 6.9 kg within 20 weeks of withdrawal. An 11-pound gain over four weeks without the drug is consistent with what the pharmacology would predict.

Where does the social media noise diverge from clinical reality?

The optimism in "I still feel like I'm doing pretty good" is understandable, but it obscures a few things the comment section probably won't mention. First, the 11-pound regain in one month is not trivial. It represents roughly 73 percent of her total loss from her apparent starting point, though we don't know her baseline weight. Second, TikTok GLP-1 content overwhelmingly treats these drugs as a tool you can pick up and put down without consequence, which the SURMOUNT-4 data specifically contradicts for sustained results. Third, the "poor choices" framing risks implying that behavioral willpower is the primary variable, when GLP-1 receptor agonists work substantially by modulating appetite-regulating circuits in the hypothalamus. When the drug is gone, those circuits revert. This is biology, not a discipline failure, and conflating the two gives viewers an inaccurate mental model of how these medications actually function.

What should you actually know?

If you're on tirzepatide and thinking about a break, the clinical picture suggests the risks are real and dose-dependent. The SURMOUNT-4 trial used maintenance doses up to 15 mg weekly, and even at those levels, discontinuation led to substantial rebound. For someone at a lower maintenance dose, the trajectory could differ, but probably not favorably. Restarting after a break typically requires retitrating from a lower dose to manage gastrointestinal side effects, which means it's not as simple as picking up where you left off. There's also emerging observational data suggesting that repeated cycles of loss and regain on GLP-1 drugs may affect long-term metabolic adaptation, though this hasn't been confirmed in large trials yet. The honest bottom line: if cost, access, or side effects are driving breaks, those are legitimate conversations to have with a prescribing clinician, not problems to manage alone based on how you "feel" week to week.